Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis
Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Kenei Sada, Takayuki Katsuyama, Yoshia Miyawaki, Eri Katsuyama, Mariko Narazaki, Noriko Tatebe, Katsue Watanabe, Tomoko Kawabata, Jun Wada
Graduate School of Medicine Dentistry and Pharmaceutical Sciences
Graduate School of Environmental and Life Science
Academic Field of Medicine, Dentistry and Pharmaceutical Sciences
We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.
https://doi.org/10.2169/internalmedicine.8683-16
Antineutrophil cytoplasmic antibody-associated vasculitis
Hypertrophic pachymeningitis
10.2169/internalmedicine.8683-16
Dive into the research topics of 'Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis'. Together they form a unique fingerprint.
Neurogenic Diabetes Insipidus Medicine & Life Sciences 100%
Diabetes Insipidus Medicine & Life Sciences 87%
Antineutrophil Cytoplasmic Antibodies Medicine & Life Sciences 85%
Vasculitis Medicine & Life Sciences 70%
Etanercept Medicine & Life Sciences 56%
Mycophenolic Acid Medicine & Life Sciences 53%
Rituximab Medicine & Life Sciences 49%
Meningitis Medicine & Life Sciences 45%
Ohashi, K., Morishita, M., Watanabe, H., Sada, K., Katsuyama, T., Miyawaki, Y., Katsuyama, E., Narazaki, M., Tatebe, N., Watanabe, K., Kawabata, T., & Wada, J. (2017). Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis. Internal Medicine, 56(21), 2943-2948. https://doi.org/10.2169/internalmedicine.8683-16
Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis. / Ohashi, Keiji; Morishita, Michiko; Watanabe, Haruki et al.
In: Internal Medicine, Vol. 56, No. 21, 2017, p. 2943-2948.
Ohashi, K, Morishita, M, Watanabe, H, Sada, K, Katsuyama, T, Miyawaki, Y, Katsuyama, E, Narazaki, M, Tatebe, N, Watanabe, K, Kawabata, T & Wada, J 2017, 'Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis', Internal Medicine, vol. 56, no. 21, pp. 2943-2948. https://doi.org/10.2169/internalmedicine.8683-16
Ohashi K, Morishita M, Watanabe H, Sada K, Katsuyama T, Miyawaki Y et al. Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis. Internal Medicine. 2017;56(21):2943-2948. doi: 10.2169/internalmedicine.8683-16
Ohashi, Keiji ; Morishita, Michiko ; Watanabe, Haruki et al. / Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis. In: Internal Medicine. 2017 ; Vol. 56, No. 21. pp. 2943-2948.
@article{878aee86932b43a98e8384edc811540d,
title = "Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis",
abstract = "We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.",
keywords = "Antineutrophil cytoplasmic antibody-associated vasculitis, Diabetes insipidus, Etanercept, Hypertrophic pachymeningitis, Rituximab",
author = "Keiji Ohashi and Michiko Morishita and Haruki Watanabe and Kenei Sada and Takayuki Katsuyama and Yoshia Miyawaki and Eri Katsuyama and Mariko Narazaki and Noriko Tatebe and Katsue Watanabe and Tomoko Kawabata and Jun Wada",
note = "Funding Information: This work was supported by the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan under Grant <nannti-ippann-044>. Publisher Copyright: {\textcopyright} 2017 The Japanese Society of Internal Medicine.",
doi = "10.2169/internalmedicine.8683-16",
journal = "Internal Medicine",
publisher = "Japanese Society of Internal Medicine",
T1 - Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis
AU - Ohashi, Keiji
AU - Morishita, Michiko
AU - Watanabe, Haruki
AU - Sada, Kenei
AU - Katsuyama, Takayuki
AU - Miyawaki, Yoshia
AU - Katsuyama, Eri
AU - Narazaki, Mariko
AU - Tatebe, Noriko
AU - Watanabe, Katsue
AU - Kawabata, Tomoko
AU - Wada, Jun
N1 - Funding Information: This work was supported by the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan under Grant <nannti-ippann-044>. Publisher Copyright: © 2017 The Japanese Society of Internal Medicine.
N2 - We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.
AB - We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.
KW - Antineutrophil cytoplasmic antibody-associated vasculitis
KW - Diabetes insipidus
KW - Etanercept
KW - Hypertrophic pachymeningitis
KW - Rituximab
U2 - 10.2169/internalmedicine.8683-16
DO - 10.2169/internalmedicine.8683-16
JO - Internal Medicine
JF - Internal Medicine